ReviewFrontiers in oncology2025
Roles of long non-coding RNA
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cancer in transition: discovery of tumor-intrinsic transcriptional programs shaping the immune and microenvironmental landscape.Biomarker research · 2026Review
- Long non-coding RNA POC1B-AS1 depletion represses colorectal cancer progression through the microRNA-625-5p/FOXK1 axis.American journal of translational research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Digestive system cancers, including hepatocellular carcinoma (HCC), gastric cancer (GC), pancreatic cancer (PC), and colorectal cancer (CRC), pose a significant global health burden with high morbidity and mortality rates. Their tumorigenesis and progression are driven by complex interactions between genetic alterations and environmental factors. In recent years, long non-coding RNAs (lncRNAs) have emerged as critical regulators in cancer initiation, metastasis, and drug resistance through epigenetic modulation, transcriptional regulation, and post-transcriptional modifications. Among them, HULC, a well-characterized oncogenic lncRNA, was initially identified in HCC due to its remarkable upregulation. Subsequent studies have revealed that HULC is aberrantly overexpressed in multiple gastrointestinal malignancies, including GC, PC, and CRC, and its expression levels strongly correlate with advanced clinical stage, metastatic potential, and poor patient prognosis. Mechanistically, HULC exerts its oncogenic effects by interacting with genes, RNA, and proteins to promoting the Warburg effect, and inducing epithelial-mesenchymal transition (EMT), thereby facilitating tumor progression. This review comprehensively summarizes recent advances in understanding the biological roles, molecular mechanisms, and clinical implications of HULC in digestive system cancers. Furthermore, we discuss its potential as a novel diagnostic biomarker and therapeutic target, providing insights into precision medicine strategies for gastrointestinal malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.